NOX2-IN-2 (compound 33) is a potent inhibitor of NOX2, disrupting the p47phox-p22phox protein-protein interaction with a dissociation constant (K i) of 0.24 μM. It effectively suppresses reactive oxygen species (ROS) production originating from NOX2 in cellular contexts [1].

NOX2-IN-1 (compound 10) serves as an inhibitor of the enzyme nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2). It specifically disrupts the p47phox-p22phox protein-protein interaction, exhibiting high binding affinities and potent activity within cellular assays [1].

NoxA1ds acetate is a potent and selective NADPH oxidase 1 (NOX1) inhibitor (IC50 : 20 nM). Exhibits selectivity for NOX1 over NOX2, NOX4, NOX5 and xanthine oxidase. Inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. Attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro.

APX-115 (Ewha-18278) (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor (Kis: 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4). APX-115 effectively prevents kidney injury.

ML-090 is NOX1-specific inhibitor(IC50 = 90 nM) which is >100 selectivity for NOX1 over NOX2, NOX3, NOX4 (all IC50s >10 μM).

GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays).

Potent and selective NADPH oxidase 1 (NOX1) inhibitor (IC50 = 20 nM). Exhibits selectivity for NOX1 over NOX2, NOX4, NOX5 and xanthine oxidase. Inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. Attenuates VEGF-induced human pulmonary

4',6,7-Trimethoxyisoflavone promotes wound healing through NOX2 induction, which leads to collective migration and MMP activation.

Phox-I2 is an NOX2-specific inhibitor. Phox-I2 reverts ROS-accumulation and leads to refusion of mitochondrial networks.

Phox-I1 is a NOX2 inhibitor targeting the interactive site of p67phox with Rac GTPase.

APX-115 free base (Ewha-18278 free base) (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor (Kis: 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4). APX-115 effectively prevents kidney injury.

(Rac)-Nebivolol ((Rac)-R 065824) is a racemic isomer of Nebivolol. Nebivolol is a selective antagonist of β1-adrenergic receptor (IC 50= 0.8 nM). Nebivolol shows Vasodilatory activity. In the early stages of ethanol-induced cardiac toxicity, Nebivolol can prevent up-regulation of Nox2/NADPH oxidase and lipoperoxidation.

NoxA1ds TFA is a potent and selective inhibitor of NADPH oxidase 1 (NOX1), with an inhibition concentration (IC50) of 20 nM, demonstrating selectivity over NOX2, NOX4, NOX5, and xanthine oxidase. It effectively inhibits NOX1-derived O2- production in HT-29 human colon cancer cells and attenuates VEGF-induced migration of human pulmonary artery endothelial cells under hypoxic conditions in vitro.

GLX351322 is NADPH Oxidase 4 Inhibitor with IC50 of 5 μM.